RVMDW — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 197,559,000 | 197,232,000 | -373,149,000 | -407,457,000 | 4,303,514,000 | 615,908,000 | 1,902,011,000 |
| Jun 2026 | 0 | — | -505,132,000 | -644,371,000 | 4,323,270,000 | 815,435,000 | 1,717,032,000 |
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,431,372,000
Investing CF
$-1,331,075,000
Financing CF
$3,171,885,000
CapEx
$-9,445,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,374,746,000
Inventory
$11,018,000
Receivables
$230,724,000
ST Investments
$3,035,477,000
EBIT TTM
$-1,791,171,000
Pretax Income TTM
$-1,872,889,000
Interest Exp TTM
$81,718,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$197,559,008
EBITDA
$-1,675,138,944
Free Cash Flow
$-886,292,352
Enterprise Value
—
Total Cash
$3,651,385,088
Total Debt
$1,211,414,016
Shares Out
—
Trailing EPS
—
Book Value
$11.11
ROE
-93.6%
ROA
-32.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | 1,631,297,000 | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | 2,265,204,000 | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | 1,826,194,000 | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | 685,188,000 | -224,401,000 |
TTM Snapshot
Revenues TTM
$7,768,000
NetIncome TTM
$-1,768,285,000
OpCashFlow TTM
—
Assets (Latest)
$4,323,270,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $247.70B | $457.93 | — |
| GILD | GILEAD SCIENCES, INC. | $211.18B | $170.26 | — |
| MRNA | Moderna, Inc. | $82.56B | $206.80 | — |
| ARGX | ARGENX SE | $58.92B | $947.52 | — |
| BIIB | BIOGEN INC. | $37.07B | $250.79 | — |
News headlines (Yahoo Finance, 1h cache)
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
2026-11-17 17:13 · Yahoo
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
2026-11-16 18:00 · Yahoo
RevMed CEO on tackling “complex” launch for wonder pancreatic drug
2026-11-16 17:15 · Yahoo
AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results
2026-11-13 13:30 · Yahoo
What Sent Revolution Medicines Stock Lower?
2026-11-12 15:45 · Yahoo
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 12:00 · Yahoo
Stanley Druckenmiller’s Best Buy Is Already Up 29%. Is It Too Late to Follow Him?
2026-11-11 05:03 · Yahoo
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
2026-11-10 13:55 · Yahoo
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
2026-11-08 16:35 · Yahoo
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
2026-11-08 15:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.